JDEPF yields 2.23% · JNJ yields 2.13%● Live data
📍 JDEPF pulled ahead of the other in Year 1
Combined, JDEPF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JDEPF + JNJ for your $10,000?
JDE Peet's N.V., together with its subsidiaries, provides various coffee and tea products and solutions to serve consumer needs worldwide. The company operates through CPG Europe, CPG LARMEA, CPG APAC, Out-of-Home, and Peet's segments. It offers multi-serve coffee, and single-serve and double-shot coffee capsules; and pads and pods, instant coffee, whole beans, ready-to-drink coffee beverages, various leaf and packaged tea, and professional tea products, as well as rents or sells professional solutions and complementary coffee systems. The company sells its products under the Douwe Egberts, Kenco, Peet's, L'OR, Stumptown, TiOra, Gevalia, Pickwick, PILAO, Intelligentsia, Senseo, Jacobs, Moccona, Super, OldTown, Ofçay, Mighty Leaf Tea, and Tassimo brands through CPG and out-of-home sales channels. It operates 505 coffee stores under the Peet's, Intelligentsia, Stumptown, OldTown, and 12Oz brands in the United States, China, Malaysia, and Italy, as well as through webshops, and third-party e-tailers and e-commerce marketplaces. The company serves various businesses, such as hotels, hospitals, restaurants, cruise liners, and retirement homes, as well as distributors for distribution to the customer; and offices, universities, airports, and sports venues. JDE Peet's N.V. was incorporated in 2018 and is headquartered in Amsterdam, the Netherlands.
Full JDEPF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.